Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152629 | 1.00 | RET (0.41) | RETMAP2K3PLAUTP53ADORA2A | |
| SCHEMBL5152639 | 0.92 | PLAU (0.40) | RETPLAUTP53ADORA2APOLB | |
| SCHEMBL5149017 | 0.91 | TP53 (0.43) | RETPLAUTP53ADORA2APOLB | |
| SCHEMBL5147937 | 0.91 | TP53 (0.37) | RETPLAUTP53ADORA2APOLB | |
| SCHEMBL5152804 | 0.90 | MAP2K3 (0.41) | RETMAP2K3ADORA2A | |
| SCHEMBL5152750 | 0.89 | ADORA2A (0.45) | RETADORA2A | |
| SCHEMBL5149227 | 0.89 | HPGDS (0.41) | RETADORA2A | |
| SCHEMBL5147958 | 0.86 | ADORA2A (0.39) | RETTP53ADORA2APOLB | |
| SCHEMBL5149107 | 0.85 | TP53 (0.37) | RETMAP2K3TP53ADORA2APOLB | |
| SCHEMBL5147991 | 0.85 | TP53 (0.37) | RETMAP2K3TP53ADORA2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | claimed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | claimed |
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | RET 2434/4885MAP2K3 3138/4885PLAU 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.